S2Cbio

오늘 벤처인증을 받았습니다. 특별히 투자유치를 준비하는 것은 아니지만, 한발짝씩 앞으로 가는 것같습니다.

The certificate for S2Cbio as a venture company was granted yesterday. A small step but a big step for S2Cbio.

, #벤처인증

S2Cbio와 일동제약이 항혈전치료 First-in-class 치료제 개발하기로 하였습니다. 저희가 발굴한 Validated target, hit compound를 기반으로 일봉의 Platform과 결합하여 3년이내에 후보물질을 개발하기로 하였습니다.
S2Cbio는 바이오텍생태계에 씨앗될 타겟, 선도물질을 발굴하여 Biotech 혹은 pharma와 같이 개발하여 서로의 가치를 상승시킬 목적으로 만들어진 NRDO입니다. 같이 일할 수 있는 기회가 많았으면 좋겠습니다.

, #일동제약,

일동제약, 벤처기업 ‘에스투시바이오’와 항혈전제 신약 연구개발 협약 일동제약은 23일 신약개발 벤처기업 ‘에스투시바이오’와 신개념 항혈전제 개발을 위한 공동연구 협약을 체결했다. 에스투시바이오는 자체 플랫폼과 원천기술을 활용해 신약 후보물질을 도…

I post the history of S2Cbio for your information. Just in the L/I posting today...

Yonsei University TLO and S2Bio agree a deal in August 12. S2Cbio will acquire the right on ANO6 and will exercise the screening technology and the information of the early hit for discovery of novel class of a drug.

Dr. KY Nam of Pharos I&BT visited S2Cbio today. Dr. Nam introduced the business plan and pipeline of Pharos, and we discussed the on-going projects of S2Cbio (PLDi, GLP1RA, PAR2 antagonist). Pharos will review today meeting and will arrange future meeting for the further discussion.

S2CBio offers research collaboration to identify small-molecule hits of novel biological mechanism. Professor Han's group successfully identified novel PPI inhibitors of LRS and LagD interaction for modulation m-TOR pathway. (https://www.nature.com/articles/s41467-017-00785-0)
Now the detail mechanism of this small molecule in PNAS online.(http://www.pnas.org/content/early/2018/05/18/1801287115.short)

Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction Leucyl-tRNA synthetase (LRS) is a leucine sensor of the mTORC1 pathway. Here, the authors identify inhibitors of the GTPase activating function of LRS, not affecting its catalytic activity, and demonstrate that the leucine sensor function of LRS can be a new target for mTORC1 inhibition.